Part of University of Arkansas System, Board of Trustees of The University of Arkansas is a company headquartered in Fayetteville, AR, that owns and operates radio stations.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

Glenmark Pharmaceuticals SA, part of Glenmark Pharmaceuticals Ltd., is a Swiss company located in Neuch��tel. The firm develops and Manufactures pharmaceuticals.

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Shanghai Kangdai Biomedical Technology Co., Ltd., established on 2009-04-17, Business scope includes research and development of biomedicine,Biotechnology Services,Engaged in the import and export business of goods. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.

SBI Biotech mainly focuses on dendritic cell platform-based innovative drug development. As an R&D-type bio-venture company, we do not have abundant human resource like in the case of general pharmaceutical companies and we mainly focus on our activity in the early stages of drug development. Particularly, our biggest hurdle is the clinical studies / clincal trials which we need huge budgets to support our clinical trials on human to test drug safety and efficacy. We have been trying to utilize our human and financial resources efficiently by early licensing of our pipelines in the preclinical stage, instead of performing the clinical trials by our own. For the early stage licensing, we have tried to provide excellent products by the world-leading research team with the expertise in dendritic cell manipulation. We have successfully proven the feasibility of the business model since we succeeded in licensing of our early stage dendritic cells targeting antibody, anti-ILT7 antibody to MedImmune. We will continue our efforts in early licensing activity by our highly competitive research team.

Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Good health and a happy life is something all people rightly aspire to. They believe everyone on the planet deserves access to quality health care. Finding affordable solutions to today's health care challenges demands cutting-edge science, highly talented and motivated people and above all the ability to innovate. Innovation and continuous improvement are the heartbeat of their company. Their mission is to make health care more affordable, increasing access to important medicines through the provision of high quality small molecule generics, and new biological and new chemical entities.

Shanghai Celgen Biopharma Co., Ltd. (上海赛金) is mainly engaged in the research and development, production, and sales of biological medicinal products of recombinant proteins and monoclonal antibodies used in the field of immune disease and cancer. As a biopharmaceutical enterprise engaged professionally in researching and developing, producing, and selling biopharmaceutical products, Celgen Biopharma has already built up a professional platform for the phages antibody screening library, a CHO cell clone development platform recognized by FDA/EMEA, and a world-class platform to culture CHO cells without serum or antibiotics, an advanced purification platform, a complete analysis platform, a technology development platform of ""quality stems from design"", a vitro drug active research platform, and a vivo activity evaluation technology platform.

Suzhou Yuntai Biomedical Technology Co., Ltd., established on 2013-01-06, Business scope includes biotechnology products,Research and development of in vitro diagnostic reagents and related equipment,technology transfer,Technical Services;biotechnology product(non-medical,non edible),Sales of laboratory equipment and consumables.Production,Sales:Class I medical device,Class II medical device,Class III medical devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

ZIOPHARM Oncology is an American biopharmaceutical company headquartered in Boston, Massachusetts, that develops novel therapeutics for the treatment of cancer. ZIOPHARM has three oncology therapeutics in clinical development: IL-12 DNA, indibulin and darinaparsin. In 2011, ZIOPHARM established a partnership with Intrexon Corporation to develop and commercialize DNA therapeutics based on Intrexon's synthetic biology technology platform. The exclusive channel partnership between Intrexon and ZIOPHARM has been established specifically for the field of human oncologic therapeutics. Under the partnership, ZIOPHARM will be responsible for conducting preclinical and clinical development of candidates, as well as for other aspects of manufacturing and the commercialization of the candidates.

Olon is one of the largest European developers and manufacturers, supplying APIs for the pharmaceutical industry worldwide both, for Generic as well as for contract manufacturing. OLON owns 5 manufacturing sites in northern Italy (Rodano, Settimo Torinese, Garbagnate Milanese, Mulazzano and Dorno) with more than 800 employees while INFA Group, with more than 400 employees, has 2 manufacturing sites in Italy, Labochim and Sifavitor, and 1 in Spain, Derivados Químicos.

Manufactures pharmaceuticals and diagnostic substances

Knopp Biosciences is a drug discovery and development company that focuses on delivering breakthrough treatments in neurological disorders through innovation, experience, and partnership. The company targets diseases imposing high costs on the healthcare system, with patient populations clearly identifiable using validated biomarkers or genetic testing. The company's goal is to accelerate and advance treatment, change the course of diseases, and improve the lives of the patients and their families. Knopp Biosciences was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands.